With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...

As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, a prodrug approach emerges to potentially ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Japanese biopharma Nxera Pharma has secured $35m in milestone payments from Neurocrine Biosciences following positive Phase ...

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

Schizophrenia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in ...